Lilly's eczema drug shows durable long-term response in late-stage study

Lilly's eczema drug shows durable long-term response in late-stage study | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv A drone view shows the Eli Lilly logo on one of the company's offices in San Diego, California, U.S., November 21, 2025. REUTERS/Mike Blake Purchase Licensing Rights, opens new tab March 27 (Reuters) - Eli Lilly (LLY.N), opens new tabsaid on Friday that its eczema drug showed durable results in a late-stage post-marketing study, suc ...